

INFORMATION DISCLOSURE TRANSMITTAL	Docket No. P0017/7000
<p>Applicant: Ernest Mestrovic, Michaela Horvat, Maja Devcic, Amir Avdagic, Dominik Ciccic and Marina Marinkovic</p> <p>Serial No: TBA</p> <p>Filed: Herewith</p> <p>For: SOLID FORMS OF MONTELUKAST ACID</p> <p>Examiner: TBA</p> <p>Art Unit: TBA</p>	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In keeping with the duty of candor and good faith owed to the Patent and Trademark Office, Applicant wishes to bring information to the attention of the Examiner. The filing of this statement shall not be construed as a representation that a search has been made or as an admission that this information is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

**Enclosures**

- ☒ A form PTO-1449 listing this information is attached
- ☒ Copies of documents cited, other than U.S. patents and published U.S. patent applications, are enclosed.
- ☐ Copies of the cited documents are not enclosed because

**Fees**

- ☒ This statement is filed before the later of: (1) three months of (i) the filing of a national application or (ii) the entry date for the national stage of an international application; (2) the mailing date of a first office action on the merits; or (3) the mailing date of a first office action on the merits following the filing of a Request for Continued Examination. No fee is due.
- ☐ This statement is filed before the mailing date of a final office action, a notice of allowance or an action that otherwise closes prosecution, *and*
  - ☐ The submission fee of \$180.00 under 37 CFR §1.17(p) is enclosed, *or*
  - ☐ The following certification is made:
    - ☐ each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, *or*
    - ☐ no item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☐ This statement is filed on or before payment of the issue fee, the submission fee of \$180.00 under 37 CFR §1.17(p) is enclosed, *and*
  - ☐ each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, *or*

- ☐ no item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.


**Payment**

- ☐ A check in the amount of the submission fee is enclosed.  
☐ Charge Account No. 02-3038 in the amount of the submission fee. A duplicate of this transmittal sheet is attached.

**Authorization to Charge Additional Fees**

- ☒ The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17 required by the attached paper and during the entire pendency of this application to Account No. 02-3038.

Respectfully submitted,



Date:

7/27/06

M. Lawrence Oliverio, Esq. Reg. No. 30,915  
KUDIRKA & JOBSE, LLP  
Customer Number 021127  
Tel: (617) 367-4600 Fax: (617) 367-4656

IAP11 Rec'd PCT/PTO 27 JUL 2006

**Docket No. P0017/7000**

Applicant:	Ernest Mestrovic, Michaela Horvat, Maja Devcic, Amir Avdagic, Dominik Ciccic and Marina Marinkovic
Serial No:	TBA
Filed:	Herewith
For:	SOLID FORMS OF MONTELUKAST ACID
Examiner:	TBA
Art Unit:	TBA

[illegible]

Exam Inits	Cite No.	Cy	Number	Kind Code	Patentee or Applicant Name	Publication Date	
	1	WO	2005/040123	A	Synhton B.V.	05/06/2005	Abstract
	2	WO	2004/108679	A	Morepen Laboratories Limited	12/16/2004	Abstract
	3	WO	03/066598	A	Dr. Reddy's Laboratories Ltd.	08/14/2003	Abstract
	4	EP	0480717	A	Merck Frosst Canada Inc.	04/15/1992	Abstract

Date  
Considered